Quarterly report (Form 10-Q)
Caris Life Sciences 10-Q for Quarter ended Jun 30, 2026
Filing excerpt
Revenue from clinical cases for patients covered by Medicare represented approximately 38.9% and 49.7% of our molecular profiling services revenue for the three months ended June 30, 2026 and 2025, respectively.